Sun Bo, Li Rong, Ji Ning, Liu Han, Wang Hongxiang, Chen Chao, Bai Long, Su Jiacan, Chen Juxiang
Department of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Mater Today Bio. 2025 Jan 3;30:101443. doi: 10.1016/j.mtbio.2025.101443. eCollection 2025 Feb.
Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, characterized by a high mortality rate and a poor prognosis. The blood-brain barrier (BBB) and the blood-tumor barrier (BTB) present significant obstacles to the efficacy of tumor-targeted pharmacotherapy, thereby impeding the therapeutic potential of numerous candidate drugs. Targeting delivery of adequate doses of drug across the BBB to treat GBM has become a prominent research area in recent years. This emphasis has driven the exploration and evaluation of diverse technologies for GBM pharmacotherapy, with some already undergoing clinical trials. This review provides a thorough overview of recent advancements and challenges in targeted drug delivery for GBM treatment. It specifically emphasizes systemic drug administration strategies to assess their potential and limitations in GBM treatment. Furthermore, this review highlights promising future research directions in the development of intelligent drug delivery systems aimed at overcoming current challenges and enhancing therapeutic efficacy against GBM. These advancements not only support foundational research on targeted drug delivery systems for GBM but also offer methodological approaches for future clinical applications.
胶质母细胞瘤（GBM）是最常见的原发性恶性脑肿瘤，其特点是死亡率高、预后差。血脑屏障（BBB）和血肿瘤屏障（BTB）对肿瘤靶向药物治疗的疗效构成了重大障碍，从而阻碍了众多候选药物的治疗潜力。近年来，将足够剂量的药物靶向递送至血脑屏障以治疗GBM已成为一个突出的研究领域。这种重视推动了对GBM药物治疗的多种技术的探索和评估，其中一些技术已经在进行临床试验。本综述全面概述了GBM治疗中靶向药物递送的最新进展和挑战。它特别强调全身给药策略，以评估其在GBM治疗中的潜力和局限性。此外，本综述突出了智能药物递送系统开发中未来有前景的研究方向，旨在克服当前挑战并提高对GBM的治疗效果。这些进展不仅支持GBM靶向药物递送系统的基础研究，还为未来的临床应用提供了方法学途径。
